Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects
Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects
The purpose of this study is to learn if BMS-646256 can cause weight loss in men and women
 who are:

 -  overweight with high blood pressure or high cholesterol or

 -  obese

 The safety of this treatment will also be studied
Inclusion Criteria:

 -  Men and women, ages ≥18 to ≤70 years old with a Body Mass Index (BMI) ≥30 to ≤45 kg/m²
 OR BMI >27 to <30 kg/m² with hypertension and/or dyslipidemia defined as:

 -  Hypertension defined as treatment with an antihypertensive agent or mean systolic
 blood pressure ≥140 and ≤160 mmHg and/or diastolic blood pressure ≥ 90 and ≤ 105 mmHg

 -  Dyslipidemia defined as stable dose treatment with a statin, fibrate or ezetimibe for
 ≥ 6 weeks and/or triglycerides ≥ 150 and ≤ 600 mg/dL, LDL ≥ 130 and ≤ 300 mg/dL, or
 HDL < 40 mg/dL

 Exclusion Criteria:

 -  Type 1 or 2 diabetes mellitus

 -  history of MI in the prior 6 months

 -  history of heart failure

 -  history of symptomatic arrhythmia

 -  active hepatic disease

 -  any documented muscle disease

 -  history of neurological symptoms or disease (including but not limited to tremor,
 ataxia, dizziness, neuropathy, or episodes of confusion, history of seizures, stroke
 or TIA)

 -  known history of major psychiatric conditions (e.g. schizophrenia anxiety disorder,
 dementia or bipolar disorder as defined by DSM IV criteria)

 -  history of depression or suicide attempt or ideation

 -  previous history of surgical procedures for weight loss (e.g., stomach stapling,
 bypass)

 -  uncontrolled blood pressure